---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-005888"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:08:08.573895+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants NRx Pharma transfer to Capital Market; compliance due April 16, 2024

## Summary
- Nasdaq Hearings Panel grants transfer to Capital Market; must comply with all criteria by April 16, 2024.
- Company believes it has satisfied the $35M market value of listed securities requirement.
- Must evidence compliance with $1.00 minimum bid price for ten consecutive business days by April 16.
- Aims to file first NDA for NRX-100 (ketamine) for acute suicidal depression this quarter.
- Phase 2b/3 trial results for NRX-101 in suicidal bipolar depression expected before compliance date.

## SEC filing metadata
- accession: 0001104659-24-005888
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924005888/0001104659-24-005888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924005888/tm243930d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-005888
- JSON: https://secwatch.observer/filing/0001104659-24-005888.json
- Plain text: https://secwatch.observer/filing/0001104659-24-005888.txt

## Key facts
- Listing & Compliance Notices
  NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5550(a)(2)
  source text: October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which hearing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924005888/0001104659-24-005888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.